000 01856cam  2200397zi 4500
0019.871533
003CaOODSP
00520221107163420
006m     o  d f      
007cr cn|||||||||
008190412t20192019onc     o    f000 0 eng d
020 |a9780660304977
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH14-318/2019E-PDF
24500|aGuidance document : |breconsideration of decisions issued for human drug and natural health product submissions / |cpublished by authority of the Minister of Health ; Health Products and Food Branch.
24630|aReconsideration of decisions issued for human drug and natural health product submissions
24617|aHealth Canada guidance document : |breconsideration of decisions issued for human drug and natural health product submissions
264 1|a[Ottawa] : |bHealth Canada = Santé Canada, |c2019.
264 4|c©2019
300 |a1 online resource (32 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Ligne directrice : révision des décisions sur les présentations de drogue pour usage humain et les produits de santé naturels.
500 |aCover title.
500 |a"Effective Date: 2019/04/01."
500 |a"Pub.: 190002."
530 |aIssued also in print format.
69207|2gccst|aDrugs
69207|2gccst|aGovernment policy
7101 |aCanada. |bHealth Canada.
7101 |aCanada. |bHealth Products and Food Branch.
77508|tLigne directrice : |w(CaOODSP)9.871540
7760#|tReconsideration of decisions issued for human drug and natural health product submissions.|w(CaOODSP)9.871537
85640|qPDF|s429 KB|uhttps://publications.gc.ca/collections/collection_2019/sc-hc/H14-318-2019-eng.pdf